NCT00000596

CompletedPhase 2

Diffuse Fibrotic Lung Disease

National Heart, Lung, and Blood Institute (NHLBI)Source

Compare

Other study identifiers

Sponsor study identifier

402

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

0 countries

Sites

N/A

Timeline

Study Start

June 1978

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

January 1983

Actual (reported)

Brief Summary

To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis. Also, to evaluate the use of intermittent, short-term, high-dose intravenous corticosteroids in patients with sarcoidosis. There were actually four separate clinical trials.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Reported enrollment (type unavailable): Not reported
Study completion date: January 1983
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 1978
Date type not reported
This date has not been verified as actual or estimated.
Study Completion
January 1983
Actual (reported)
First Submitted
October 27, 1999
Actual (reported)
First Posted
October 28, 1999
Actual (reported)

Last Updated: November 26, 2013
Status Verified: February 2002
Last Update Submitted: November 25, 2013

Conditions

Lung Diseases Pulmonary Fibrosis Sarcoidosis

Interventions

prednisoneDrug

cyclophosphamideDrug

dapsoneDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

No eligibility criteria

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

National Heart, Lung, and Blood Institute (NHLBI)
NIHlead

Related Publications (1)

Keogh BA, Bernardo J, Hunninghake GW, Line BR, Price DL, Crystal RG. Effect of intermittent high dose parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1983 Jan;127(1):18-22. doi: 10.1164/arrd.1983.127.1.18.
PMID: 6849542BACKGROUND

MeSH Terms

Conditions

Lung DiseasesPulmonary FibrosisSarcoidosis

Interventions

PrednisoneCyclophosphamideDapsone

Condition Hierarchy (Ancestors)

Respiratory Tract DiseasesLung Diseases, InterstitialFibrosisPathologic ProcessesPathological Conditions, Signs and SymptomsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type: interventional
Phase: phase 2
Allocation: RANDOMIZED
Purpose: TREATMENT
Sponsor Type: NIH

Study Record Dates

First Submitted

October 27, 1999

First Posted

October 28, 1999

Study Start

June 1978

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

January 1983

Actual (reported)

NCT06212596

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Phase 2Completed

NCT00540644

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Phase 2Completed

NCT01442779

Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

Phase 2Completed

NCT02192489

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Phase 2Withdrawn

NCT00005276

A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)

Completed

NCT00005531

Genetic Epidemiology of Sarcoidosis

Completed

Hypersensitivity, Delayed

Hypersensitivity

Immune System Diseases

Intervention Hierarchy (Ancestors)

PregnadienediolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsPhosphoramide MustardsNitrogen Mustard CompoundsMustard CompoundsHydrocarbons, HalogenatedHydrocarbonsOrganic ChemicalsPhosphoramidesOrganophosphorus CompoundsSulfonesSulfur Compounds

Last Updated

November 26, 2013

Record last verified: 2002-02

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00000596
Data provider: ClinicalTrials.gov
Source updated: 2013-11-26
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:44 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Study Completion

First Submitted

First Posted

Conditions

Interventions

Eligibility Criteria

Sponsors & Collaborators

Related Publications (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record